TY - JOUR T1 - Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge? JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm DO - 10.1136/ejhpharm-2022-003305 SP - ejhpharm-2022-003305 AU - Julie Hias AU - Laura Hellemans AU - Karolien Walgraeve AU - Jos Tournoy AU - Christophe Vandenbriele AU - Lucas Van Aelst AU - Lorenz Roger Van der Linden Y1 - 2022/05/18 UR - http://ejhp.bmj.com/content/early/2022/05/18/ejhpharm-2022-003305.abstract N2 - Heart failure (HF) occurs predominantly in older adults. HF patients have an increased risk for an acute exacerbation, which commonly requires hospitalisation. Such a worsening HF (WHF) event has an impact on prognosis. Vericiguat is a novel agent which has been shown to reduce the HF hospitalisation risk in patients with a recent WHF event. It is not fully clear how to position this novel agent in geriatric HF inpatients. ER -